Fourth-generation cephalosporins: A review of in vitro activity, pharmacokinetics, pharmacodynamics and clinical utility

Clinical Microbiology and Infection

Volumn 3, Issue SUPPL. 1, 1997, Pages s87-s101

  Garau, Javier ^a   Wilson, Walter ^b   Wood, Martin ^c   Carlet, Jean ^d  

^a Cirugía Ortopédica y Traumatología Hospital Universitaria Mutua Terrassa   (Spain)

^b MAYO CLINIC   (United States)

^c BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

^d SAINT JOSEPH HOSPITAL   (France)

Author keywords

Cefepime; Cefpirome; Fourth generation cephalosporin; Neutropenia; Pneumonia; Sepsis; Zwitterion

Indexed keywords

EID: 0003074342     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1997.tb00649.x     Document Type: Article

References (15)

1. Neu HC. The crisis in antibiotic resistance. Science 1992; 257: 1064-73.
2. Spencer RC, Bauernfeind A, Garcia-Rodriguez J, et al. Surveillance of current resistance of nosocomial pathogens to antibiotics. [This supplement].
3. Jones RN, Baquero F, Privitera G, Inoue M, Wiedemann B. Inducible β-lactamase-mediated resistance to third-generation cephalosporins. [This supplement].
4. Jones RN. The current and future impact of antimicrobial resistance among nosocomial bacteria] pathogens. Diagn Microbiol Infect Dis 1993; 15: S3-10.
5. Livermore DM. Mechanism of resistance to β-lactam antibiotics. Scand J Infect Dis 1991; 78 (suppl): S7-16.
6. Pechere J-C, Wilson W, Neu H. Laboratory assessment of antibacterial activity of zwitterionic 7-methoxyimino cephalosporins. J Antimicrob Chemother 1995; 36: 757-71.
7. Sanders CC. β-lactamases of Gram-negative bacteria: New challenges for new drugs. Clin Infect Dis 1992; 14: 1089-99.
8. Neu HC. The place of cephalosporins in antibacterial treatment of infectious diseases. J Antimicrob Chemother 1980; 6 (suppl A): 1-10.
9. Neu HC. β-lactam antibiotics: Structural relationships affecting in vitro activity and pharmacologic properties. Rev Infect Dis 1986; (suppl 3): S287-359.
10. Sanders CC. Inducible β-lactamase and non-hydrolytic resistance mechanisms. J Antimicrob Chemother 1984; 13: 1-3.
11. Sanders WE, Sanders CC. Inducible β-lactamases: clinical and epidemiological implications for use of newer cephalosporins. Rev Infect Dis 1988; 10: 830-8.
12. Livermore DM and Yuan M. Antibiotic resistance and production of extended-spectrum β-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-24.
13. Wolff M, Brun-Buisson C, Lode H, Mathai D, Lewi D, Pittet D. The changing epidemiology of severe infections in the ICU. [This supplement].
14. Jarvis WR, Martone W. Predominant pathogens in hospital infections. J Antimicrob Chemother 1992; 29 (suppl A): S19-24.
15. Klugman K, Goldstein F, Kohno S, Baquero F. The role of fourth-generation cephalosporins in treatment of infections caused by penicillin-resistant streptococci. [This supplement].